Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Immunity & Ageing
Published in: Immunity & Ageing 1/2014

Open Access 01-12-2014 | Research

Antibody responses to intradermal or intramuscular MF59-adjuvanted influenza vaccines as evaluated in elderly institutionalized volunteers during a season of partial mismatching between vaccine and circulating A(H3N2) strains

Authors: Barbara Camilloni, Michela Basileo, Angela Di Martino, Isabella Donatelli, Anna Maria Iorio

Published in: Immunity & Ageing | Issue 1/2014

Login to get access

Abstract

Background

The age-related weakening of the immune system makes elderly subjects less responsive to influenza vaccination. In the last years, two “enhanced vaccines” were licensed for individuals aged ≥65 years, one being a subunit vaccine (Fluad®) containing the MF59 adjuvant administered intramuscularly (IM-MF59) and the other one a split non-adjuvanted vaccine administered intradermally (Intanza® 15mcg) (ID). In the present study, we evaluated and compared the antibody responses against the three vaccine antigens and heterovariant A(H3N2) circulating viruses induced by IM-MF59 and ID influenza vaccines in 80 elderly institutionalized volunteers (40 per group) during the Winter season 2011–2012.

Results

Hemagglutination inhibiting (HI) antibody titers were assessed in blood samples collected before, 1 and 6 months after vaccination. One month after vaccination both the IM-MF59 and ID vaccines induced increases in HI titers against all the three vaccine strains. The results in the two groups were similar against the A(H3N2) and A(H1N1) strains. Responses against the B strain typically tended to be higher after ID than IM-MF59, yet both vaccines stimulated lower responses against the B strain than against the two A strains. The two vaccines induced favorable results also against four epidemic drifted A(H3N2) viruses circulating in Winter 2011–2012. Six months after vaccination, the HI titers decreased in both groups.

Conclusion

The responses induced by IM-MF59 and ID vaccines in institutionalized elderly people were similar against the A(H3N2) and A(H1N1) strains but frequently higher, for the ID, against the B strain. The two vaccines induced positive responses against drifted A(H3N2) circulating viruses.
Appendix
Available only for authorised users
Literature
1.
Fiore AE, Uyeki TM, Broder K, Finelli L, Euler GL, Singleton JA, Iskander JK, Wortley PM, Shay DK, Bresee JS, Cox NJ, Centers for Disease Control and Prevention (CDC): Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices (ACIP), 2010. MMWR Recomm Rep. 2010, 59 (rr-08): 1-62.PubMed
2.
Kovaiou RD, Herndler-Brandstetter D, Grubeck-Loebenstein B: Age-related changes in immunity: implications for vaccination in the elderly. Expert Rev Mol Med. 2007, 9: 1-17.CrossRefPubMed
3.
Goodwin K, Viboud C, Simonsen L: Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine. 2006, 24: 1159-1169. 10.1016/j.vaccine.2005.08.105.CrossRefPubMed
4.
Grubeck-Loebenstein B, Della Bella S, Iorio AM, Michel J-P, Pawelec G, Solana R: Immunosenescence and vaccine failure in the elderly. Aging Clin Exp Res. 2009, 21: 201-209. 10.1007/BF03324904.CrossRefPubMed
5.
Durando P, Iudici R, Alicino C, Alberti M, de Florentiis D, Ansaldi F, Icardi G: Adjuvants and alternative routes of administration towards the development of the ideal influenza vaccine. Human Vaccines. 2011, 7: 211-216.CrossRefPubMed
6.
O’Hagan DT: MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. Expert Rev Vaccines. 2007, 6: 699-710. 10.1586/14760584.6.5.699.CrossRefPubMed
7.
Nicolas JF, Guy B: Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice. Expert Rev Vaccines. 2008, 7: 1201-1214. 10.1586/14760584.7.8.1201.CrossRefPubMed
8.
Beyer WEP, Nauta JJP, Palache AM, Giezeman KM, Osterhaus ADME: Immunogenicity and safety of inactivated influenza vaccines in primed populations: a systematic literature review and meta-analysis. Vaccine. 2011, 29: 5785-5792. 10.1016/j.vaccine.2011.05.040.CrossRefPubMed
9.
Holland D, Booy R, De Looze F, Eizenberg P, McDonald J, Karrasch J, McKeirnan M, Salem H, Mills G, Reid J, Weber F, Saville M: Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J Infect Dis. 2008, 198: 650-658. 10.1086/590434.CrossRefPubMed
10.
Arnou R, Icardi G, De Decker M, Ambrozaitis A, Kazek MP, Weber F, Van Damme P: Intradermal influenza vaccine for older adults: a randomized controlled multicenter phase III study. Vaccine. 2009, 27: 7304-7312. 10.1016/j.vaccine.2009.10.033.CrossRefPubMed
11.
Ansaldi F, Orsi A, de Florentiis D, Parodi V, Rappezzo E, Coppelli M, Durando P, Icardi G: Head-to-head comparison of an intradermal and a virosome influenza vaccine in patients over the age of 60. Human Vaccines & Immunotherapeutics. 2013, 9: 591-598. 10.4161/hv.23240.CrossRef
12.
Scheifele DW, McNeil SA, Ward BJ, Dionne M, Cooper C, Cleman B, Loeb M, Rubinstein E, McElhaney J, Hatchette T, Li Y, Montomoli E, Schneeberg A, Bettinger JA, Halperin SA, Research Network CI: Safety, immunogenicity, and tolerability of three influenza vaccines in older adults. Human Vaccines and Immunotherapeutics. 2013, 9: 2460-2473.PubMedCentralCrossRefPubMed
13.
Carrat F, Flahault A: Influenza vaccine: the challenge of antigenic drift. Vaccine. 2007, 25: 6852-6862. 10.1016/j.vaccine.2007.07.027.CrossRefPubMed
14.
Orsi A, Ansaldi F, de Florentiis D, Ceravolio A, Parodi V, Canepa P, Coppelli M, Icardi G, Durando P: Cross-protection against drifted influenza viruses: options offered by adjuvanted and intradermal vaccines. Human Vaccines & Immunotherapeutics. 2013, 9: 582-590. 10.4161/hv.23239.CrossRef
15.
Katz JM, Hancock K, Xu X: Serologic assays for influenza surveillance, diagnosis and vaccine evaluation. Expert Rev Anti Infect Ther. 2011, 9: 669-683. 10.1586/eri.11.51.CrossRefPubMed
16.
Committee for Medicinal Products for Human Use (CHMP): DHHS/FDA/CBER. Guidance for Industry, Clinical Data Needed to Support the Licensure of Pandemic Influenza Vaccines, Draft Guidance 2006. Guideline on Clinical Evaluation of New Vaccines. 2005
17.
Coudeville L, Bailleux F, Riche B, Megas F, Andre P, Ecochard R: Relationship between haemagglutination inhibiting antibody titres and clinical protection against influenza: development and application of a bayedsian random-effects model. BMC Med Res Methodol. 2010, 10: 18-10.1186/1471-2288-10-18.PubMedCentralCrossRefPubMed
18.
Beyer WE, Palache AM, Lüchters G, Nauta J, Osterhaus ADME: Seroprotection rate, mean fold increase, seroconversion rate: which parameter adequately expresses seroresponse to influenza vaccination?. Virus Res. 2004, 103: 125-132. 10.1016/j.virusres.2004.02.024.CrossRefPubMed
19.
20.
Keitel WA, Cate TR, Couch RB: Efficacy of sequential annual vaccination with inactivated influenza vaccines. Am J Epidemiol. 1988, 127: 353-364.PubMed
21.
Iorio AM, Camilloni B, Basileo M, Neri M, Lepri E, Spighi M: Effects of repeated annual influenza vaccination on antibody responses against unchanged vaccine antigens in elderly frail institutionalized volunteers. Gerontology. 2007, 53: 411-418.CrossRefPubMed
22.
Camilloni B, Neri M, Lepri E, Basileo M, Sigismondi N, Puzelli S, Donatelli I, Iorio AM: An influenza B outbreak during the 2007/2008 winter among appropriately immunized elderly people living in a nursing home. Vaccine. 2010, 28: 7536-7541. 10.1016/j.vaccine.2010.08.064.CrossRefPubMed
23.
Van Damme P, Arnou R, Kafeja F, Fiquet A, Richard P, Thomas S, Meghlaoui G, Samson SI, Ledesma E: Evaluation of non-inferiority of intradermal versus adjuvanted seasonal influenza vaccine using two serological techniques: a randomized comparative study. BMC Infec Dis. 2010, 10: 134-10.1186/1471-2334-10-134.CrossRef
24.
25.
Harmon MW: Influenza viruses. Laboratory diagnosis of viral infections. Edited by: Lenette H. 1992, New York: Dekker, 515-534. 2
26.
Puzelli S, Frezza F, Fabiani C, Ansaldi F, Campitelli L, Lin YP, Gregory V, Bennett M, D’Argaro P, Campello C, Crovari P, Hay A, Donatelli I: Changes in the hemagglutinins and neuraminidases of human influenza B viruses isolated in Italy during the 2001–02, 2002–03 and 2003–04 seasons. J Med Virol. 2004, 74: 629-640. 10.1002/jmv.20225.CrossRefPubMed
27.
Kumar S, Tamura K, Nei M: MEGA3: integrated software for molecular evolutionary genetics analysis and sequence alignment. Brief Bioinform. 2004, 5: 150-163. 10.1093/bib/5.2.150.CrossRefPubMed
Metadata
Title
Antibody responses to intradermal or intramuscular MF59-adjuvanted influenza vaccines as evaluated in elderly institutionalized volunteers during a season of partial mismatching between vaccine and circulating A(H3N2) strains
Authors
Barbara Camilloni
Michela Basileo
Angela Di Martino
Isabella Donatelli
Anna Maria Iorio
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Immunity & Ageing / Issue 1/2014
Electronic ISSN: 1742-4933
DOI
https://doi.org/10.1186/1742-4933-11-10

Other articles of this Issue 1/2014

Immunity & Ageing 1/2014 Go to the issue

Review

The 21st century epidemic: infections as inductors of neuro-degeneration associated with Alzheimer’s Disease

Editorial

Alzheimer’s disease and infections, where we stand and where we go

Research

Bereavement reduces neutrophil oxidative burst only in older adults: role of the HPA axis and immunesenescence

Research

Characterization of recovery, repair, and inflammatory processes following contusion spinal cord injury in old female rats: is age a limitation?

Methodology

LATEX sensitization in elderly: allergological study and diagnostic protocol

Research

Age-related differences in polyfunctional T cell responses
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits